File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001-2009)

TitleAntipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001-2009)
Authors
KeywordsExtrapyramidal Side Effects
Older Patients
Prescription Patterns
Schizophrenia
Issue Date2012
Citation
International Journal Of Clinical Pharmacology And Therapeutics, 2012, v. 50 n. 7, p. 500-504 How to Cite?
AbstractObjective: This study surveyed the prescribing patterns of antipsychotic medications in Asian older schizophrenia patients with extrapyramidal side effects (EPS) during the period between 2001 and 2009. Method: Information on 848 hospitalized patients with schizophrenia aged 60 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (2001 - 2009). Data from those patients with reported EPS from 8 Asian countries and territories including China, Hong Kong, Japan, Korea, Singapore, Taiwan, India and Malaysia were analyzed. The cross-sectional data of socio-demographic and clinical characteristics and antipsychotic prescriptions were collected using a standardized protocol and data collection procedure. Results: Of the 309/848 (36%) patients suffering from EPS, 210 patients (210/309; 68.0%) received at least one type of first generation antipsychotic (FGA), and 99 (99/309; 32.0%) received second generation antipsychotics (SGAs) only. Of SGAs prescribed in patients with EPS, risperidone was the most commonly used (100/309; 32.4%) followed by olanzapine (33/309; 10.7%) and quetiapine (25/309; 8.1%). Conclusions: FGAs were frequently used in Asian older schizophrenia patients with EPS. Considering the potential adverse effects of FGAs on existing EPS, the reasons for the frequent use of FGAs need to be urgently identified. ©2012 Dustri-Verlag Dr. K. Feistle.
Persistent Identifierhttp://hdl.handle.net/10722/171984
ISSN
2015 Impact Factor: 1.129
2015 SCImago Journal Rankings: 0.400
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorXiang, YTen_US
dc.contributor.authorKreyenbuhl, Jen_US
dc.contributor.authorDickerson, FBen_US
dc.contributor.authorUngvari, GSen_US
dc.contributor.authorWang, CYen_US
dc.contributor.authorSi, TMen_US
dc.contributor.authorLee, EHMen_US
dc.contributor.authorChiu, HFKen_US
dc.contributor.authorLai, KYCen_US
dc.contributor.authorHe, YLen_US
dc.contributor.authorYang, SYen_US
dc.contributor.authorChong, MYen_US
dc.contributor.authorTan, CHen_US
dc.contributor.authorKua, EHen_US
dc.contributor.authorFujii, Sen_US
dc.contributor.authorSim, Ken_US
dc.contributor.authorYong, MKHen_US
dc.contributor.authorTrivedi, JKen_US
dc.contributor.authorChung, EKen_US
dc.contributor.authorUdomratn, Pen_US
dc.contributor.authorChee, KYen_US
dc.contributor.authorSartorius, Nen_US
dc.contributor.authorShinfuku, Nen_US
dc.date.accessioned2012-10-30T06:19:16Z-
dc.date.available2012-10-30T06:19:16Z-
dc.date.issued2012en_US
dc.identifier.citationInternational Journal Of Clinical Pharmacology And Therapeutics, 2012, v. 50 n. 7, p. 500-504en_US
dc.identifier.issn0946-1965en_US
dc.identifier.urihttp://hdl.handle.net/10722/171984-
dc.description.abstractObjective: This study surveyed the prescribing patterns of antipsychotic medications in Asian older schizophrenia patients with extrapyramidal side effects (EPS) during the period between 2001 and 2009. Method: Information on 848 hospitalized patients with schizophrenia aged 60 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (2001 - 2009). Data from those patients with reported EPS from 8 Asian countries and territories including China, Hong Kong, Japan, Korea, Singapore, Taiwan, India and Malaysia were analyzed. The cross-sectional data of socio-demographic and clinical characteristics and antipsychotic prescriptions were collected using a standardized protocol and data collection procedure. Results: Of the 309/848 (36%) patients suffering from EPS, 210 patients (210/309; 68.0%) received at least one type of first generation antipsychotic (FGA), and 99 (99/309; 32.0%) received second generation antipsychotics (SGAs) only. Of SGAs prescribed in patients with EPS, risperidone was the most commonly used (100/309; 32.4%) followed by olanzapine (33/309; 10.7%) and quetiapine (25/309; 8.1%). Conclusions: FGAs were frequently used in Asian older schizophrenia patients with EPS. Considering the potential adverse effects of FGAs on existing EPS, the reasons for the frequent use of FGAs need to be urgently identified. ©2012 Dustri-Verlag Dr. K. Feistle.en_US
dc.languageengen_US
dc.relation.ispartofInternational Journal of Clinical Pharmacology and Therapeuticsen_US
dc.subjectExtrapyramidal Side Effectsen_US
dc.subjectOlder Patientsen_US
dc.subjectPrescription Patternsen_US
dc.subjectSchizophreniaen_US
dc.titleAntipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001-2009)en_US
dc.typeArticleen_US
dc.identifier.emailLee, EHM:edwinlhm@hku.hken_US
dc.identifier.authorityLee, EHM=rp01575en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.5414/CP201683en_US
dc.identifier.pmid22541750-
dc.identifier.scopuseid_2-s2.0-84863687393en_US
dc.identifier.hkuros224687-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84863687393&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume50en_US
dc.identifier.issue7en_US
dc.identifier.spage500en_US
dc.identifier.epage504en_US
dc.identifier.isiWOS:000307134300007-
dc.identifier.scopusauthoridXiang, YT=35241398400en_US
dc.identifier.scopusauthoridKreyenbuhl, J=6602795669en_US
dc.identifier.scopusauthoridDickerson, FB=7003825018en_US
dc.identifier.scopusauthoridUngvari, GS=36938621200en_US
dc.identifier.scopusauthoridWang, CY=35345843000en_US
dc.identifier.scopusauthoridSi, TM=55268740100en_US
dc.identifier.scopusauthoridLee, EHM=7406967099en_US
dc.identifier.scopusauthoridChiu, HFK=55035304900en_US
dc.identifier.scopusauthoridLai, KYC=55194376000en_US
dc.identifier.scopusauthoridHe, YL=35313337300en_US
dc.identifier.scopusauthoridYang, SY=7406951183en_US
dc.identifier.scopusauthoridChong, MY=55266934400en_US
dc.identifier.scopusauthoridTan, CH=7402817882en_US
dc.identifier.scopusauthoridKua, EH=55195892100en_US
dc.identifier.scopusauthoridFujii, S=7401814463en_US
dc.identifier.scopusauthoridSim, K=55152349200en_US
dc.identifier.scopusauthoridYong, MKH=47161681100en_US
dc.identifier.scopusauthoridTrivedi, JK=55192624400en_US
dc.identifier.scopusauthoridChung, EK=55267798900en_US
dc.identifier.scopusauthoridUdomratn, P=6602459819en_US
dc.identifier.scopusauthoridChee, KY=36100061600en_US
dc.identifier.scopusauthoridSartorius, N=7102159482en_US
dc.identifier.scopusauthoridShinfuku, N=7003855366en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats